{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:36:34Z","timestamp":1792193794630,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T00:00:00Z","timestamp":1321488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1245\/s10434-011-2134-0","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T08:30:28Z","timestamp":1321518628000},"page":"1326-1333","source":"Crossref","is-referenced-by-count":14,"title":["Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer"],"prefix":"10.1245","volume":"19","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-I.","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pietzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,17]]},"reference":[{"key":"2134_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/107327481101800105","volume":"18","author":"DG Teoh","year":"2011","unstructured":"Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control. 2011;18:31\u201343.","journal-title":"Cancer Control."},{"key":"2134_CR2","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ejca.2008.07.042","volume":"44","author":"FA Eskens","year":"2008","unstructured":"Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer. 2008;44:2350\u20136.","journal-title":"Eur J Cancer."},{"key":"2134_CR3","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902\u20138.","journal-title":"J Clin Oncol."},{"key":"2134_CR4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","volume":"121","author":"RA Burger","year":"2011","unstructured":"Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230\u20138.","journal-title":"Gynecol Oncol."},{"key":"2134_CR5","first-page":"4743","volume":"30","author":"M Koskas","year":"2010","unstructured":"Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Dara\u00ef E. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Res. 2010;30:4743\u20137.","journal-title":"Anticancer Res."},{"key":"2134_CR6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.05.031","volume":"114","author":"GP Sfakianos","year":"2009","unstructured":"Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE 4th, Straughn JM Jr. The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol. 2009;114:424\u20136.","journal-title":"Gynecol Oncol."},{"key":"2134_CR7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.ajog.2008.08.048","volume":"200","author":"E Ch\u00e9reau","year":"2009","unstructured":"Ch\u00e9reau E, Stefanescu D, Selle F, Rouzier R, Dara\u00ef E. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol. 2009;200:e15\u20136.","journal-title":"Am J Obstet Gynecol."},{"key":"2134_CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","volume":"117","author":"LM Randall","year":"2010","unstructured":"Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117:497\u2013504.","journal-title":"Gynecol Oncol."},{"key":"2134_CR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ygyno.2010.10.002","volume":"120","author":"N Bansal","year":"2011","unstructured":"Bansal N, Hoffman M. Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab. Gynecol Oncol. 2011;120:313\u20134.","journal-title":"Gynecol Oncol."},{"key":"2134_CR10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2006.05.006","volume":"102","author":"BJ Monk","year":"2006","unstructured":"Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140\u20134.","journal-title":"Gynecol Oncol."},{"key":"2134_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/17474108.4.2.133","volume":"4","author":"S Janczar","year":"2009","unstructured":"S. Janczar, JS Graham, AJW Paige, H Gabra. Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Rev Obstet. Gynecol. 2009;4:133\u201347.","journal-title":"Expert Rev Obstet. Gynecol."},{"key":"2134_CR12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","volume":"26","author":"B Gruenberger","year":"2008","unstructured":"Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830\u20135.","journal-title":"J Clin Oncol."},{"key":"2134_CR13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","volume":"206","author":"SK Reddy","year":"2008","unstructured":"Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96\u2013106.","journal-title":"J Am Coll Surg."},{"key":"2134_CR14","doi-asserted-by":"crossref","first-page":"LBA5006","DOI":"10.1200\/jco.2011.29.18_suppl.lba5006","volume":"29","author":"G Kristensen","year":"2011","unstructured":"Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011;29:LBA5006.","journal-title":"J Clin Oncol."},{"key":"2134_CR15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324\u201330.","journal-title":"Ann Surg Oncol."},{"key":"2134_CR16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jso.21288","volume":"99","author":"J Sehouli","year":"2009","unstructured":"Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424\u20137.","journal-title":"J Surg Oncol."},{"key":"2134_CR17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2003-41864","volume":"125","author":"J Sehouli","year":"2003","unstructured":"Sehouli J, K\u00f6nsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. \u201cIMO\u201d- intraoperative mapping of ovarian cancer. Zentralbl Gynakol. 2003;125:129\u201335.","journal-title":"Zentralbl Gynakol."},{"key":"2134_CR18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0015-0282(16)57062-9","volume":"62","author":"Adhesion Scoring Group","year":"1994","unstructured":"Adhesion Scoring Group, Improvement of interobserver reproducibility of adhesion scoring systems. Fertil Steril. 1994;62:984\u20138.","journal-title":"Fertil Steril."},{"key":"2134_CR19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s10350-004-0954-8","volume":"48","author":"Z Cohen","year":"2005","unstructured":"Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, et al. Prevention of postoperative abdominal adhesions by a novel, glycerol\/sodium hyaluronate\/carboxymethylcellulose\u2013based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum. 2005;48:1130\u20139.","journal-title":"Dis Colon Rectum."},{"key":"2134_CR20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0002-9378(87)90261-4","volume":"156","author":"International Federation of Gynecology and Obstetrics","year":"1987","unstructured":"International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987:156:263\u20134.","journal-title":"Am J Obstet Gynecol."},{"key":"2134_CR21","first-page":"2675","volume":"31","author":"K Pietzner","year":"2011","unstructured":"Pietzner K, Schmuck RB, Fotopoulou C, Gellermann J, Ismaeel F, Cho CH, et al. Long term combination treatment with bevacizumab, pegylated liposomal Doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature. Anticancer Res. 2011;31:2675\u20137.","journal-title":"Anticancer Res."},{"key":"2134_CR22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.20938","volume":"97","author":"DA August","year":"2008","unstructured":"August DA, Serrano D, Poplin E. \u201cSpontaneous\u201d delayed colon and rectal anastomotic complications associated with Bevacizumab therapy. J Surg Oncol. 2008;97:180\u20135.","journal-title":"J Surg Oncol."},{"key":"2134_CR23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/02841860601009471","volume":"46","author":"I Wolf","year":"2007","unstructured":"Wolf I, Urban D, Pfeffer R, Catane R, Aderka D. High incidence of fistula formation during bevacizumab treatment in rectal cancer patients. Acta Oncol. 2007;46:550\u20133.","journal-title":"Acta Oncol."},{"key":"2134_CR24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/gut.2006.112524","volume":"56","author":"A Adenis","year":"2007","unstructured":"Adenis A, Vanseymortier L, Foissey D, Colombel JF. Bevacizumab and postponed suture leakages after surgery for ulceration cancer. Gut. 2007;56:734.","journal-title":"Gut."},{"key":"2134_CR25","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10350-007-0231-8","volume":"50","author":"EJ Ley","year":"2007","unstructured":"Ley EJ, Vukasin P, Kaiser AM, Ault G, Beart RW. Delayed rectovaginal fistula: a potential complication of bevacizumab (Avastin). Dis Colon Rectum. 2007;50:930.","journal-title":"Dis Colon Rectum."},{"key":"2134_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","volume":"105","author":"ES Han","year":"2007","unstructured":"Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105:3\u20136.","journal-title":"Gynecol Oncol."},{"key":"2134_CR27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","volume":"116","author":"JP Diaz","year":"2010","unstructured":"Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, dos Santos LA, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2010;116:335\u20139.","journal-title":"Gynecol Oncol."},{"key":"2134_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000320602","volume":"79","author":"A S\u00e1nchez-Mu\u00f1oz","year":"2010","unstructured":"S\u00e1nchez-Mu\u00f1oz A, Mendiola C, P\u00e9rez-Ruiz E, Rodr\u00edguez-S\u00e1nchez CA, Jurado JM, Alonso-Carri\u00f3n L, et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology. 2010;79:98\u2013104.","journal-title":"Oncology."},{"key":"2134_CR29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","volume":"107","author":"JC Chura","year":"2007","unstructured":"Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107:326\u201330.","journal-title":"Gynecol Oncol."},{"key":"2134_CR30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19:577\u201382.","journal-title":"Ann Oncol."},{"key":"2134_CR31","doi-asserted-by":"crossref","unstructured":"Khasraw M, Holodny A, Goldlust SA, Deangelis LM. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. 2011 May 4 [Epub ahead of print].","DOI":"10.1093\/annonc\/mdr148"},{"key":"2134_CR32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/MLG.0b013e31817c4296","volume":"118","author":"CM Burkart","year":"2008","unstructured":"Burkart CM, Grisel JJ, Hom DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008;118:1539\u201341.","journal-title":"Laryngoscope."},{"key":"2134_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","volume":"118","author":"DL Richardson","year":"2010","unstructured":"Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010;118:47\u201351.","journal-title":"Gynecol Oncol."},{"key":"2134_CR34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2010.11.009","volume":"120","author":"JL Tanyi","year":"2011","unstructured":"Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011;120:464\u20139.","journal-title":"Gynecol Oncol."},{"key":"2134_CR35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","volume":"107","author":"F Simpkins","year":"2007","unstructured":"Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107:118\u201323.","journal-title":"Gynecol Oncol."},{"key":"2134_CR36","doi-asserted-by":"crossref","unstructured":"Basbug M, Bulbuller N, Camci C, Ayten R, Aygen E, Ozercan IH, et al. The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study. Gastroenterol Res Pract. 2011;2011:578691 [Epub June 28 2011].","DOI":"10.1155\/2011\/578691"},{"key":"2134_CR37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2011.04.046","volume":"122","author":"K Kudoh","year":"2011","unstructured":"Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol. 2011;122:233\u20137.","journal-title":"Gynecol Oncol."},{"key":"2134_CR38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2011.01.009","volume":"121","author":"DM O\u2019Malley","year":"2011","unstructured":"O\u2019Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:269\u201372.","journal-title":"Gynecol Oncol."},{"key":"2134_CR39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","volume":"117","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117:152\u20138.","journal-title":"Gynecol Oncol."},{"key":"2134_CR40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","volume":"28","author":"RT Penson","year":"2010","unstructured":"Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28:154\u20139.","journal-title":"J Clin Oncol."},{"key":"2134_CR41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","volume":"115","author":"JD Hurt","year":"2009","unstructured":"Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2009;115:396\u2013400.","journal-title":"Gynecol Oncol."},{"key":"2134_CR42","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180\u20136. Erratum in: J Clin Oncol. 2008;26:1773."},{"key":"2134_CR43","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165\u201371.","journal-title":"J Clin Oncol."},{"key":"2134_CR44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2006.01.030","volume":"102","author":"DE Cohn","year":"2006","unstructured":"Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102:134\u20139.","journal-title":"Gynecol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2134-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-011-2134-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2134-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:45:38Z","timestamp":1572972338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-011-2134-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1245\/s10434-011-2134-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}